| Year |
Citation |
Score |
| 2023 |
Zhou RW, Parsons RE. Etiology of super-enhancer reprogramming and activation in cancer. Epigenetics & Chromatin. 16: 29. PMID 37415185 DOI: 10.1186/s13072-023-00502-w |
0.398 |
|
| 2023 |
Kabir M, Sun N, Hu X, Martin TC, Yi J, Zhong Y, Xiong Y, Kaniskan HÜ, Gu W, Parsons R, Jin J. Acetylation Targeting Chimera Enables Acetylation of the Tumor Suppressor p53. Journal of the American Chemical Society. PMID 37365684 DOI: 10.1021/jacs.3c04640 |
0.366 |
|
| 2023 |
Cahuzac KM, Lubin A, Bosch K, Stokes N, Shoenfeld SM, Zhou R, Lemon H, Asara J, Parsons RE. AKT activation because of PTEN loss upregulates xCT via GSK3β/NRF2, leading to inhibition of ferroptosis in PTEN-mutant tumor cells. Cell Reports. 42: 112536. PMID 37210723 DOI: 10.1016/j.celrep.2023.112536 |
0.416 |
|
| 2022 |
Zhou RW, Xu J, Martin TC, Zachem AL, He J, Ozturk S, Demircioglu D, Bansal A, Trotta AP, Giotti B, Gryder B, Shen Y, Wu X, Carcamo S, Bosch K, ... ... Parsons RE, et al. A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma. Nature Communications. 13: 6041. PMID 36253360 DOI: 10.1038/s41467-022-33377-8 |
0.345 |
|
| 2022 |
Yu X, Xu J, Cahuzac KM, Xie L, Shen Y, Chen X, Liu J, Parsons RE, Jin J. Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells. Journal of Medicinal Chemistry. PMID 36197750 DOI: 10.1021/acs.jmedchem.2c01454 |
0.346 |
|
| 2022 |
Schoenfeld DA, Zhou R, Zairis S, Su W, Steinbach N, Mathur D, Bansal A, Zachem AL, Tavarez B, Hasson D, Bernstein E, Rabadan R, Parsons R. Loss of PBRM1 alters promoter histone modifications and activates ALDH1A1 to drive renal cell carcinoma. Molecular Cancer Research : McR. PMID 35412614 DOI: 10.1158/1541-7786.MCR-21-1039 |
0.331 |
|
| 2021 |
Yu X, Xu J, Xie L, Wang L, Shen Y, Cahuzac KM, Chen X, Liu J, Parsons RE, Jin J. Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders. Journal of Medicinal Chemistry. PMID 34855399 DOI: 10.1021/acs.jmedchem.1c01476 |
0.323 |
|
| 2021 |
Xu J, Yu X, Martin TC, Bansal A, Cheung K, Lubin A, Stratikopoulos E, Cahuzac KM, Wang L, Xie L, Zhou R, Shen Y, Wu X, Yao S, Qiao R, ... ... Parsons R, et al. AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild-type KRAS and BRAF by destabilizing Aurora kinase B. Cancer Discovery. PMID 34301793 DOI: 10.1158/2159-8290.CD-20-0815 |
0.373 |
|
| 2021 |
Pappas K, Martin TC, Wolfe AL, Nguyen CB, Su T, Jin J, Hibshoosh H, Parsons R. NOTCH and EZH2 collaborate to repress PTEN expression in breast cancer. Communications Biology. 4: 312. PMID 33750924 DOI: 10.1038/s42003-021-01825-8 |
0.338 |
|
| 2020 |
Molina-Sánchez P, Ruiz de Galarreta M, Yao MA, Lindblad KE, Bresnahan E, Bitterman E, Martin TC, Rubenstein T, Nie K, Golas J, Choudhary S, Bárcena-Varela M, Elmas A, Miguela V, Ding Y, ... ... Parsons RE, et al. Cooperation between distinct cancer driver genes underlies inter-tumor heterogeneity in hepatocellular carcinoma. Gastroenterology. PMID 32814112 DOI: 10.1053/J.Gastro.2020.08.015 |
0.311 |
|
| 2020 |
Ozturk S, Mathur D, Zhou RW, Mulholland D, Parsons R. Leflunomide triggers synthetic lethality in PTEN-deficient prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 32661432 DOI: 10.1038/S41391-020-0251-1 |
0.341 |
|
| 2020 |
Garcia-Carracedo D, Cai Y, Qiu W, Saeki K, Friedman RA, Lee A, Li Y, Goldberg EM, Stratikopoulos EE, Parsons R, Lu C, Efstratiadis A, Philipone EM, Yoon AJ, Su GH. PIK3CA and p53 mutations promote 4NQO-initated head and neck tumor progression and metastasis in mice. Molecular Cancer Research : McR. PMID 32152233 DOI: 10.1158/1541-7786.Mcr-19-0549 |
0.443 |
|
| 2020 |
Parsons R. Discovery of the PTEN Tumor Suppressor and Its Connection to the PI3K and AKT Oncogenes. Cold Spring Harbor Perspectives in Medicine. 10. PMID 31932465 DOI: 10.1101/Cshperspect.A036129 |
0.496 |
|
| 2019 |
Ma A, Stratikopoulos E, Park KS, Wei J, Martin TC, Yang X, Schwarz M, Leshchenko V, Rialdi A, Dale B, Lagana A, Guccione E, Parekh S, Parsons R, Jin J. Discovery of a first-in-class EZH2 selective degrader. Nature Chemical Biology. PMID 31819273 DOI: 10.1038/S41589-019-0421-4 |
0.403 |
|
| 2019 |
Steinbach N, Hasson D, Mathur D, Stratikopoulos EE, Sachidanandam R, Bernstein E, Parsons RE. PTEN interacts with the transcription machinery on chromatin and regulates RNA polymerase II-mediated transcription. Nucleic Acids Research. PMID 31169889 DOI: 10.1093/Nar/Gkz272 |
0.41 |
|
| 2019 |
Parsons R. Restoring tumor suppression. Science. 364: 633-634. PMID 31097653 DOI: 10.1126/Science.Aax5526 |
0.371 |
|
| 2018 |
Mazumdar M, Moshier EL, Özbek U, Parsons R. Ten Essential Practices for Developing or Reforming a Biostatistics Core for a NCI Designated Cancer Center. Jnci Cancer Spectrum. 2: pky010. PMID 31360841 DOI: 10.1093/Jncics/Pky010 |
0.302 |
|
| 2018 |
Stratikopoulos EE, Kiess N, Szabolcs M, Pegno S, Kakit C, Wu X, Poulikakos PI, Cheung P, Schmidt H, Parsons R. Mouse ER+/PIK3CA breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents. Oncogene. PMID 30076411 DOI: 10.1038/S41388-018-0436-4 |
0.449 |
|
| 2018 |
Parsons RE. Abstract SY22-02: Metabolic vulnerability of PTEN mutant cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Sy22-02 |
0.457 |
|
| 2017 |
Riquelme SA, Hopkins BD, Wolfe AL, DiMango E, Kitur K, Parsons R, Prince A. Cystic Fibrosis Transmembrane Conductance Regulator Attaches Tumor Suppressor PTEN to the Membrane and Promotes Anti Pseudomonas aeruginosa Immunity. Immunity. 47: 1169-1181.e7. PMID 29246444 DOI: 10.1016/J.Immuni.2017.11.010 |
0.357 |
|
| 2017 |
Pappas K, Xu J, Zairis S, Resnick-Silverman L, Abate F, Steinbach N, Ozturk S, Saal LH, Su T, Cheung P, Schmidt H, Aaronson SA, Hibshoosh H, Manfredi JJ, Rabadan R, ... Parsons R, et al. p53 maintains baseline expression of multiple tumor suppressor genes. Molecular Cancer Research : McR. PMID 28483946 DOI: 10.1158/1541-7786.Mcr-17-0089 |
0.708 |
|
| 2017 |
Yadav SS, Li J, Stockert JA, Herzog B, O'Connor J, Garzon-Manco L, Parsons R, Tewari AK, Yadav KK. Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications. Translational Oncology. 10: 357-366. PMID 28342996 DOI: 10.1016/J.Tranon.2017.01.011 |
0.412 |
|
| 2017 |
Mathur D, Stratikopoulos E, Ozturk S, Steinbach N, Pegno S, Schoenfeld S, Yong R, Murty VV, Asara JM, Cantley LC, Parsons R. PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition. Cancer Discovery. PMID 28255082 DOI: 10.1158/2159-8290.Cd-16-0612 |
0.444 |
|
| 2017 |
Wolfe AL, Hopkins BD, Riquelme SA, Kitur K, Ozturk S, Kang K, Remark R, Rahman A, Lin C, Merad M, Szabolcs M, Chen S, Prince A, Parsons R. Abstract 334: PTEN-L regulates epithelial growth and macrophage function Cancer Research. 77: 334-334. DOI: 10.1158/1538-7445.Am2017-334 |
0.385 |
|
| 2016 |
She QB, Gruvberger-Saal SK, Maurer M, Chen Y, Jumppanen M, Su T, Dendy M, Lau YK, Memeo L, Horlings HM, van de Vijver MJ, Isola J, Hibshoosh H, Rosen N, Parsons R, et al. Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer. Bmc Cancer. 16: 587. PMID 27484095 DOI: 10.1186/S12885-016-2609-2 |
0.677 |
|
| 2016 |
Barrows D, He JZ, Parsons R. PREX1 Protein Function is Negatively Regulated Downstream of Receptor Tyrosine Kinase Activation by p21-activated Kinases (PAKs). The Journal of Biological Chemistry. PMID 27481946 DOI: 10.1074/Jbc.M116.723882 |
0.411 |
|
| 2016 |
Chung CY, Sun Z, Mullokandov G, Bosch A, Qadeer ZA, Cihan E, Rapp Z, Parsons R, Aguirre-Ghiso JA, Farias EF, Brown BD, Gaspar-Maia A, Bernstein E. Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary Tumorigenesis. Cell Reports. PMID 27346354 DOI: 10.1016/J.Celrep.2016.06.002 |
0.439 |
|
| 2016 |
Stratikopoulos EE, Parsons RE. Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 22: 2605-10. PMID 27250929 DOI: 10.1158/1078-0432.Ccr-15-2389 |
0.473 |
|
| 2016 |
Silva J, Marshall N, Sanchez-Garcia F, Parsons R, Pe'er D. Abstract P2-06-02: BIN3 is an 8p21 tumor suppressor regulating the epithelial attachment checkpoint Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P2-06-02 |
0.399 |
|
| 2016 |
Schoenfeld D, Su W, Zairis S, Mathur D, Rabadan R, Parsons R. Abstract A24: PBRM1 alteration in clear cell renal cell carcinoma increases tumorigenicity through ALDH1A1 upregulation Cancer Research. 76. DOI: 10.1158/1538-7445.Chromepi15-A24 |
0.505 |
|
| 2015 |
Barrows D, Schoenfeld SM, Hodakoski C, Silkov A, Honig B, Couvillon A, Shymanets A, Nuernberg B, Asara JM, Parsons R. PAK kinases mediate the phosphorylation of PREX2 to initiate feedback inhibition of Rac1. The Journal of Biological Chemistry. PMID 26438819 DOI: 10.1074/Jbc.M115.668244 |
0.805 |
|
| 2015 |
Chen Y, van de Vijver MJ, Hibshoosh H, Parsons R, Saal LH. PTEN and NEDD4 in Human Breast Carcinoma. Pathology Oncology Research : Por. PMID 26276352 DOI: 10.1007/S12253-015-9971-2 |
0.695 |
|
| 2015 |
Chen H, Kleinberger JW, Takane KK, Salim F, Fiaschi-Taesch N, Pappas K, Parsons R, Jiang J, Zhang Y, Liu H, Wang P, Bender AS, Frank SJ, Stewart AF. Augmented Stat5 Signaling Bypasses Multiple Impediments to Lactogen-Mediated Proliferation in Human Beta Cells. Diabetes. PMID 26159175 DOI: 10.2337/Db15-0083 |
0.332 |
|
| 2015 |
Stratikopoulos EE, Dendy M, Szabolcs M, Khaykin AJ, Lefebvre C, Zhou MM, Parsons R. Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. Cancer Cell. 27: 837-51. PMID 26058079 DOI: 10.1016/J.Ccell.2015.05.006 |
0.48 |
|
| 2015 |
Mense SM, Barrows D, Hodakoski C, Steinbach N, Schoenfeld D, Su W, Hopkins BD, Su T, Fine B, Hibshoosh H, Parsons R. PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion. Science Signaling. 8: ra32. PMID 25829446 DOI: 10.1126/Scisignal.2005840 |
0.817 |
|
| 2015 |
Hodakoski C, Fine B, Hopkins B, Parsons R. Analysis of intracellular PTEN signaling and secretion. Methods (San Diego, Calif.). 77: 164-71. PMID 25462559 DOI: 10.1016/J.Ymeth.2014.11.008 |
0.799 |
|
| 2015 |
Nguyen HN, Yang JM, Rahdar M, Keniry M, Swaney KF, Parsons R, Park BH, Sesaki H, Devreotes PN, Iijima M. A new class of cancer-associated PTEN mutations defined by membrane translocation defects. Oncogene. 34: 3737-43. PMID 25263454 DOI: 10.1038/Onc.2014.293 |
0.47 |
|
| 2015 |
Parsons RE. Abstract IA04: PTEN regulation and output Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-Ia04 |
0.521 |
|
| 2015 |
Parsons R, Mense SM, VanHook AM. Science SignalingPodcast: 31 March 2015 Science Signaling. 8: pc8-pc8. DOI: 10.1126/Scisignal.Aab1358 |
0.512 |
|
| 2014 |
Hopkins BD, Parsons RE. Molecular pathways: intercellular PTEN and the potential of PTEN restoration therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5379-83. PMID 25361917 DOI: 10.1158/1078-0432.Ccr-13-2661 |
0.487 |
|
| 2014 |
Lau YK, Du X, Rayannavar V, Hopkins B, Shaw J, Bessler E, Thomas T, Pires MM, Keniry M, Parsons RE, Cremers S, Szabolcs M, Maurer MA. Metformin and erlotinib synergize to inhibit basal breast cancer. Oncotarget. 5: 10503-17. PMID 25361177 DOI: 10.18632/Oncotarget.2391 |
0.704 |
|
| 2014 |
Pulido R, Baker SJ, Barata JT, Carracedo A, Cid VJ, Chin-Sang ID, Davé V, den Hertog J, Devreotes P, Eickholt BJ, Eng C, Furnari FB, Georgescu MM, Gericke A, Hopkins B, ... ... Parsons R, et al. A unified nomenclature and amino acid numbering for human PTEN. Science Signaling. 7: pe15. PMID 24985344 DOI: 10.1126/Scisignal.2005560 |
0.397 |
|
| 2014 |
Hopkins BD, Hodakoski C, Barrows D, Mense SM, Parsons RE. PTEN function: the long and the short of it. Trends in Biochemical Sciences. 39: 183-90. PMID 24656806 DOI: 10.1016/J.Tibs.2014.02.006 |
0.804 |
|
| 2014 |
Hodakoski C, Hopkins BD, Barrows D, Mense SM, Keniry M, Anderson KE, Kern PA, Hawkins PT, Stephens LR, Parsons R. Regulation of PTEN inhibition by the pleckstrin homology domain of P-REX2 during insulin signaling and glucose homeostasis. Proceedings of the National Academy of Sciences of the United States of America. 111: 155-60. PMID 24367090 DOI: 10.1073/Pnas.1213773111 |
0.793 |
|
| 2014 |
Marshall N, Sanchez F, Llobet D, Barrueco RR, Castro V, Kotlia D, Pires M, Villagrasa P, Putcha P, Parsons R, Pe'er D, Silva J. Abstract 432: BIN3 is a novel 8p21 tumor suppressor gene that regulates the attachment checkpoint in epithelial cells Cancer Research. 74: 432-432. DOI: 10.1158/1538-7445.Am2014-432 |
0.726 |
|
| 2013 |
Garcia-Carracedo D, Turk AT, Fine SA, Akhavan N, Tweel BC, Parsons R, Chabot JA, Allendorf JD, Genkinger JM, Remotti HE, Su GH. Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6830-41. PMID 24132918 DOI: 10.1158/1078-0432.Ccr-13-0624 |
0.458 |
|
| 2013 |
Hopkins BD, Fine B, Steinbach N, Dendy M, Rapp Z, Shaw J, Pappas K, Yu JS, Hodakoski C, Mense S, Klein J, Pegno S, Sulis ML, Goldstein H, Amendolara B, ... ... Parsons R, et al. A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science (New York, N.Y.). 341: 399-402. PMID 23744781 DOI: 10.1126/Science.1234907 |
0.799 |
|
| 2013 |
Keniry M, Pires MM, Mense S, Lefebvre C, Gan B, Justiano K, Lau YK, Hopkins B, Hodakoski C, Koujak S, Toole J, Fenton F, Calahan A, Califano A, DePinho RA, ... ... Parsons R, et al. Survival factor NFIL3 restricts FOXO-induced gene expression in cancer. Genes & Development. 27: 916-27. PMID 23630076 DOI: 10.1101/Gad.214049.113 |
0.79 |
|
| 2013 |
Lee JT, Shan J, Zhong J, Li M, Zhou B, Zhou A, Parsons R, Gu W. RFP-mediated ubiquitination of PTEN modulates its effect on AKT activation. Cell Research. 23: 552-64. PMID 23419514 DOI: 10.1038/Cr.2013.27 |
0.456 |
|
| 2013 |
Pires MM, Hopkins BD, Saal LH, Parsons RE. Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells. Cancer Biology & Therapy. 14: 246-53. PMID 23291982 DOI: 10.4161/Cbt.23297 |
0.78 |
|
| 2013 |
Saal LH, She Q, Gruvberger-Saal SK, Maurer M, Jumppanen M, Su T, Dendy M, Lau YI, Memeo L, Ringner M, Isola J, Hibshoosh H, Rosen N, Parsons R. Abstract 869: PTEN/PI3K oncogenic pathway profiling informs an in vivo synergistic therapeutic model for basal-like breast cancer. Cancer Research. 73: 869-869. DOI: 10.1158/1538-7445.Am2013-869 |
0.713 |
|
| 2013 |
Garcia-Carracedo D, Turk AT, Fine S, Akhavan N, Tweel BC, Parsons RE, Chabot JA, Allendorf JD, Remotti H, Su GH. Abstract 1215: Loss of PTEN expression predicts poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. Cancer Research. 73: 1215-1215. DOI: 10.1158/1538-7445.Am2013-1215 |
0.482 |
|
| 2012 |
Mense S, Hodakoski C, Parsons R. PREX2, a new breed of cancer gene with too many spots? Pigment Cell & Melanoma Research. 25: 409-10. PMID 22578146 DOI: 10.1111/J.1755-148X.2012.01006.X |
0.779 |
|
| 2012 |
Xu X, Shen Y, Dewitt W, Pandya D, Bischoff FZ, Crew KD, Hershman DL, Maurer MA, Parsons R, Kalinsky K. Mutational analysis of circulating tumor cells in breast cancer patients by targeted clonal sequencing. Journal of Clinical Oncology. 30: 10516-10516. DOI: 10.1200/Jco.2012.30.15_Suppl.10516 |
0.406 |
|
| 2012 |
Serra V, Rodon J, Prudkin L, Aura C, Vivancos A, Ibrahim YH, Maurer M, Hibshoosh H, Stemke-Hale K, Jimenez J, Wang Y, Peg V, Hernandez J, Cajal SRy, Dienstmann R, ... ... Parsons R, et al. Abstract 683: Evaluation of PTEN and PIK3CA status in breast cancer for patient selection: Cross-validation between institutions Cancer Research. 72: 683-683. DOI: 10.1158/1538-7445.Am2012-683 |
0.391 |
|
| 2011 |
Keniry M, Parsons R. mTOR inhibition, the second generation: ATP-competitive mTOR inhibitor initiates unexpected receptor tyrosine kinase-driven feedback loop. Cancer Discovery. 1: 203-4. PMID 22586570 DOI: 10.1158/2159-8290.Cd-11-0157 |
0.373 |
|
| 2011 |
Grann VR, Parsons RE. Defining variations in survival of BRCA1 and BRCA2 mutation carriers. Jama. 306: 1597-8. PMID 21990304 DOI: 10.1001/Jama.2011.1476 |
0.343 |
|
| 2011 |
Deneubourg L, Ralea S, Gromova P, Parsons R, Vanderwinden JM, Erneux C. Abnormal elevated PTEN expression in the mouse antrum of a model of GIST Kit(K641E/K641E). Cellular Signalling. 23: 1857-68. PMID 21757001 DOI: 10.1016/J.Cellsig.2011.06.023 |
0.496 |
|
| 2011 |
Maurer M, Kalinsky K, Crew K, Jayasena R, Forman J, Lau Y-, Shaw J, Parsons R, Hershman D. OT3-01-13: Phase One Trial of Combined Temsirolimus, Erlotinib, and Cisplatin in Advanced Solid Tumors. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Ot3-01-13 |
0.42 |
|
| 2010 |
Sosa MS, Lopez-Haber C, Yang C, Wang H, Lemmon MA, Busillo JM, Luo J, Benovic JL, Klein-Szanto A, Yagi H, Gutkind JS, Parsons RE, Kazanietz MG. Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer. Molecular Cell. 40: 877-92. PMID 21172654 DOI: 10.1016/J.Molcel.2010.11.029 |
0.457 |
|
| 2010 |
Shen-Li H, Koujak S, Szablocs M, Parsons R. Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) mice. Cancer Biology & Therapy. 10: 1194-200. PMID 20980828 DOI: 10.4161/Cbt.10.11.13814 |
0.333 |
|
| 2010 |
Lau Y, Pires M, Shaw J, Campbell J, Parsons R, Maurer M. Abstract PD03-05: A Novel Combination Therapy for Triple Negative Breast Cancer: Erlotinib and Metformin Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-Pd03-05 |
0.712 |
|
| 2009 |
Fine B, Hodakoski C, Koujak S, Su T, Saal LH, Maurer M, Hopkins B, Keniry M, Sulis ML, Mense S, Hibshoosh H, Parsons R. Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science (New York, N.Y.). 325: 1261-5. PMID 19729658 DOI: 10.1126/Science.1173569 |
0.809 |
|
| 2009 |
Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, Barkley CR, Wu J, Nandula S, Dutta B, Xie Y, Chin YR, Kim DI, Ferris JS, Gruvberger-Saal SK, Laakso M, ... ... Parsons R, et al. 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Research. 69: 6299-306. PMID 19602588 DOI: 10.1158/0008-5472.Can-09-0820 |
0.733 |
|
| 2009 |
Gupta A, Yang Q, Pandita RK, Hunt CR, Xiang T, Misri S, Zeng S, Pagan J, Jeffery J, Puc J, Kumar R, Feng Z, Powell SN, Bhat A, Yaguchi T, ... ... Parsons R, et al. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle (Georgetown, Tex.). 8: 2198-210. PMID 19502790 DOI: 10.4161/Cc.8.14.8947 |
0.345 |
|
| 2009 |
Horst B, Gruvberger-Saal SK, Hopkins BD, Bordone L, Yang Y, Chernoff KA, Uzoma I, Schwipper V, Liebau J, Nowak NJ, Brunner G, Owens D, Rimm DL, Parsons R, Celebi JT. Gab2-mediated signaling promotes melanoma metastasis. The American Journal of Pathology. 174: 1524-33. PMID 19342374 DOI: 10.2353/Ajpath.2009.080543 |
0.466 |
|
| 2009 |
Peacock JW, Palmer J, Fink D, Ip S, Pietras EM, Mui AL, Chung SW, Gleave ME, Cox ME, Parsons R, Peter ME, Ong CJ. PTEN loss promotes mitochondrially dependent type II Fas-induced apoptosis via PEA-15. Molecular and Cellular Biology. 29: 1222-34. PMID 19103758 DOI: 10.1128/Mcb.01660-08 |
0.364 |
|
| 2009 |
Szabolcs M, Keniry M, Simpson L, Reid LJ, Koujak S, Schiff SC, Davidian G, Licata S, Gruvberger-Saal S, Murty VV, Nandula S, Efstratiadis A, Kushner JA, White MF, Parsons R. Irs2 inactivation suppresses tumor progression in Pten+/- mice. The American Journal of Pathology. 174: 276-86. PMID 19095950 DOI: 10.2353/Ajpath.2009.080086 |
0.519 |
|
| 2008 |
Leary RJ, Lin JC, Cummins J, Boca S, Wood LD, Parsons DW, Jones S, Sjöblom T, Park BH, Parsons R, Willis J, Dawson D, Willson JK, Nikolskaya T, Nikolsky Y, et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proceedings of the National Academy of Sciences of the United States of America. 105: 16224-9. PMID 18852474 DOI: 10.1073/Pnas.0808041105 |
0.446 |
|
| 2008 |
Keniry M, Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene. 27: 5477-85. PMID 18794882 DOI: 10.1038/Onc.2008.248 |
0.468 |
|
| 2008 |
Bloushtain-Qimron N, Yao J, Snyder EL, Shipitsin M, Campbell LL, Mani SA, Hu M, Chen H, Ustyansky V, Antosiewicz JE, Argani P, Halushka MK, Thomson JA, Pharoah P, Porgador A, ... ... Parsons R, et al. Cell type-specific DNA methylation patterns in the human breast. Proceedings of the National Academy of Sciences of the United States of America. 105: 14076-81. PMID 18780791 DOI: 10.1073/Pnas.0805206105 |
0.348 |
|
| 2008 |
Dey N, Crosswell HE, De P, Parsons R, Peng Q, Su JD, Durden DL. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Research. 68: 1862-71. PMID 18339867 DOI: 10.1158/0008-5472.Can-07-1182 |
0.459 |
|
| 2008 |
Xia W, Nagase S, Montia AG, Kalachikov SM, Keniry M, Su T, Memeo L, Hibshoosh H, Parsons R. BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Research. 68: 1667-74. PMID 18339845 DOI: 10.1158/0008-5472.Can-07-5276 |
0.513 |
|
| 2008 |
Saal LH, Gruvberger-Saal SK, Persson C, Lövgren K, Jumppanen M, Staaf J, Jönsson G, Pires MM, Maurer M, Holm K, Koujak S, Subramaniyam S, Vallon-Christersson J, Olsson H, Su T, ... ... Parsons R, et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nature Genetics. 40: 102-7. PMID 18066063 DOI: 10.1038/Ng.2007.39 |
0.79 |
|
| 2007 |
Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, Caparros E, Buteau J, Brown K, Perkins SL, Bhagat G, Agarwal AM, Basso G, Castillo M, Nagase S, ... ... Parsons R, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nature Medicine. 13: 1203-10. PMID 17873882 DOI: 10.1038/Nm1636 |
0.426 |
|
| 2007 |
Persson O, Krogh M, Saal LH, Englund E, Liu J, Parsons R, Mandahl N, Borg A, Widegren B, Salford LG. Microarray analysis of gliomas reveals chromosomal position-associated gene expression patterns and identifies potential immunotherapy targets. Journal of Neuro-Oncology. 85: 11-24. PMID 17634744 DOI: 10.1007/S11060-007-9383-6 |
0.656 |
|
| 2007 |
Wiencke JK, Zheng S, Jelluma N, Tihan T, Vandenberg S, Tamgüney T, Baumber R, Parsons R, Lamborn KR, Berger MS, Wrensch MR, Haas-Kogan DA, Stokoe D. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro-Oncology. 9: 271-9. PMID 17504928 DOI: 10.1215/15228517-2007-003 |
0.427 |
|
| 2007 |
Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmström P, Memeo L, Isola J, Bendahl PO, Rosen N, Hibshoosh H, Ringnér M, ... ... Parsons R, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proceedings of the National Academy of Sciences of the United States of America. 104: 7564-9. PMID 17452630 DOI: 10.1073/Pnas.0702507104 |
0.729 |
|
| 2007 |
Wong JT, Kim PT, Peacock JW, Yau TY, Mui AL, Chung SW, Sossi V, Doudet D, Green D, Ruth TJ, Parsons R, Verchere CB, Ong CJ. Pten (phosphatase and tensin homologue gene) haploinsufficiency promotes insulin hypersensitivity. Diabetologia. 50: 395-403. PMID 17195063 DOI: 10.1007/S00125-006-0531-X |
0.372 |
|
| 2007 |
Ferrando A, Palomero T, Sulis ML, Cortina M, Real PJ, Barnes K, Ciofani M, Caparros E, Perkins SL, Bhagat G, Mishra A, Basso G, Parsons R, Zúniga-Pflücker JC, Dominguez M. Mutational Loss of PTEN Induces Resistance to NOTCH1 Inhibition in T-ALL. Blood. 110: 5-5. DOI: 10.1182/Blood.V110.11.5.5 |
0.439 |
|
| 2006 |
De Clerck YA, Weissman BE, Yu D, Parsons R, Bar-Eli M, Roy-Burman P, Seewaldt VL, Cress AE, Languino LR, Batra SK, Tang CK, Sheng S, Chen WT, Chellappan S, Cheng SY, et al. Tumor progression and metastasis from genetic to microenvironmental determinants: a workshop of the tumor progression and metastasis NIH study section in honor of Dr. Martin L. Padarathsingh, May 31, 2006, Georgetown, Washington, DC. Cancer Biology & Therapy. 5: 1588-99. PMID 17224636 DOI: 10.4161/Cbt.5.12.3660 |
0.336 |
|
| 2006 |
Puc J, Placha G, Wocial B, Podsypanina K, Parsons R, Gaciong Z. Analysis of PTEN mutation in non-familial pheochromocytoma. Annals of the New York Academy of Sciences. 1073: 317-31. PMID 17102102 DOI: 10.1196/Annals.1353.037 |
0.753 |
|
| 2006 |
Gruvberger-Saal SK, Parsons R. Is the small heat shock protein alphaB-crystallin an oncogene? The Journal of Clinical Investigation. 116: 30-2. PMID 16395401 DOI: 10.1172/Jci27462 |
0.396 |
|
| 2006 |
Deleu S, Choi K, Pesesse X, Cho J, Sulis ML, Parsons R, Shears SB. Physiological levels of PTEN control the size of the cellular Ins(1,3,4,5,6)P(5) pool. Cellular Signalling. 18: 488-98. PMID 15979280 DOI: 10.1016/J.Cellsig.2005.05.017 |
0.371 |
|
| 2005 |
Parsons R. Phosphatidylinositol 3-kinase inhibitors are a triple threat to ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 7965-6. PMID 16299225 DOI: 10.1158/1078-0432.Ccr-05-1681 |
0.398 |
|
| 2005 |
Krop I, Parker MT, Bloushtain-Qimron N, Porter D, Gelman R, Sasaki H, Maurer M, Terry MB, Parsons R, Polyak K. HIN-1, an inhibitor of cell growth, invasion, and AKT activation. Cancer Research. 65: 9659-69. PMID 16266985 DOI: 10.1158/0008-5472.Can-05-1663 |
0.488 |
|
| 2005 |
Bayascas JR, Leslie NR, Parsons R, Fleming S, Alessi DR. Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Current Biology : Cb. 15: 1839-46. PMID 16243031 DOI: 10.1016/J.Cub.2005.08.066 |
0.546 |
|
| 2005 |
Kushner JA, Simpson L, Wartschow LM, Guo S, Rankin MM, Parsons R, White MF. Phosphatase and tensin homolog regulation of islet growth and glucose homeostasis. The Journal of Biological Chemistry. 280: 39388-93. PMID 16170201 DOI: 10.1074/Jbc.M504155200 |
0.346 |
|
| 2005 |
Yan Z, Cui K, Murray DM, Ling C, Xue Y, Gerstein A, Parsons R, Zhao K, Wang W. PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes. Genes & Development. 19: 1662-7. PMID 15985610 DOI: 10.1101/Gad.1323805 |
0.3 |
|
| 2005 |
Puc J, Parsons R. PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells. Cell Cycle (Georgetown, Tex.). 4: 927-9. PMID 15970699 DOI: 10.4161/Cc.4.7.1795 |
0.352 |
|
| 2005 |
Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Research. 65: 2554-9. PMID 15805248 DOI: 10.1158/0008-5472-Can-04-3913 |
0.705 |
|
| 2005 |
Sekine I, Sato M, Sunaga N, Toyooka S, Peyton M, Parsons R, Wang W, Gazdar AF, Minna JD. The 3p21 candidate tumor suppressor gene BAF180 is normally expressed in human lung cancer. Oncogene. 24: 2735-8. PMID 15735765 DOI: 10.1038/Sj.Onc.1207694 |
0.444 |
|
| 2005 |
Puc J, Keniry M, Li HS, Pandita TK, Choudhury AD, Memeo L, Mansukhani M, Murty VV, Gaciong Z, Meek SE, Piwnica-Worms H, Hibshoosh H, Parsons R. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell. 7: 193-204. PMID 15710331 DOI: 10.1016/J.Ccr.2005.01.009 |
0.44 |
|
| 2005 |
Jakob J, Nagase S, Gazdar A, Chien M, Morozova I, Russo JJ, Nandula SV, Murty VV, Li CM, Tycko B, Parsons R. Two somatic biallelic lesions within and near SMAD4 in a human breast cancer cell line. Genes, Chromosomes & Cancer. 42: 372-83. PMID 15645498 DOI: 10.1002/Gcc.20142 |
0.793 |
|
| 2004 |
Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Seminars in Cell & Developmental Biology. 15: 171-6. PMID 15209376 DOI: 10.1016/J.Semcdb.2003.12.021 |
0.501 |
|
| 2004 |
Mitchell MK, Gregersen PK, Johnson S, Parsons R, Vlahov D. The New York Cancer Project: rationale, organization, design, and baseline characteristics. Journal of Urban Health : Bulletin of the New York Academy of Medicine. 81: 301-10. PMID 15136663 DOI: 10.1093/Jurban/Jth116 |
0.322 |
|
| 2003 |
Sulis ML, Parsons R. PTEN: from pathology to biology. Trends in Cell Biology. 13: 478-83. PMID 12946627 DOI: 10.1016/S0962-8924(03)00175-2 |
0.443 |
|
| 2003 |
Parsons R, Simpson L. PTEN and cancer. Methods in Molecular Biology (Clifton, N.J.). 222: 147-66. PMID 12710685 DOI: 10.1385/1-59259-328-3:147 |
0.43 |
|
| 2002 |
Bose S, Crane A, Hibshoosh H, Mansukhani M, Sandweis L, Parsons R. Reduced expression of PTEN correlates with breast cancer progression Human Pathology. 33: 405-409. PMID 12055674 DOI: 10.1053/Hupa.2002.124721 |
0.448 |
|
| 2002 |
Wang H, Douglas W, Lia M, Edelmann W, Kucherlapati R, Podsypanina K, Parsons R, Ellenson LH. DNA mismatch repair deficiency accelerates endometrial tumorigenesis in Pten heterozygous mice. The American Journal of Pathology. 160: 1481-6. PMID 11943731 DOI: 10.1016/S0002-9440(10)62573-4 |
0.697 |
|
| 2002 |
Moinova HR, Chen WD, Shen L, Smiraglia D, Olechnowicz J, Ravi L, Kasturi L, Myeroff L, Plass C, Parsons R, Minna J, Willson JK, Green SB, Issa JP, Markowitz SD. HLTF gene silencing in human colon cancer. Proceedings of the National Academy of Sciences of the United States of America. 99: 4562-7. PMID 11904375 DOI: 10.1073/Pnas.062459899 |
0.407 |
|
| 2002 |
Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, Shen MM, Abate-Shen C. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America. 99: 2884-9. PMID 11854455 DOI: 10.1073/Pnas.042688999 |
0.481 |
|
| 2002 |
You MJ, Castrillon DH, Bastian BC, O'Hagan RC, Bosenberg MW, Parsons R, Chin L, DePinho RA. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proceedings of the National Academy of Sciences of the United States of America. 99: 1455-60. PMID 11818530 DOI: 10.1073/Pnas.022632099 |
0.48 |
|
| 2001 |
Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N, Ittmann M. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression Proceedings of the National Academy of Sciences of the United States of America. 98: 11563-11568. PMID 11553783 DOI: 10.1073/Pnas.201167798 |
0.736 |
|
| 2001 |
Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, ... ... Parsons R, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proceedings of the National Academy of Sciences of the United States of America. 98: 10320-5. PMID 11504907 DOI: 10.1073/Pnas.171060098 |
0.777 |
|
| 2001 |
Simpson L, Li J, Liaw D, Hennessy I, Oliner J, Christians F, Parsons R. PTEN Expression Causes Feedback Upregulation of Insulin Receptor Substrate 2 Molecular and Cellular Biology. 21: 3947-3958. PMID 11359902 DOI: 10.1128/Mcb.21.12.3947-3958.2001 |
0.769 |
|
| 2001 |
Simpson L, Parsons R. PTEN: life as a tumor suppressor. Experimental Cell Research. 264: 29-41. PMID 11237521 DOI: 10.1006/Excr.2000.5130 |
0.537 |
|
| 2001 |
Li Y, Podsypanina K, Liu X, Crane A, Tan LK, Parsons R, Varmus HE. Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. Bmc Molecular Biology. 2: 2. PMID 11178110 DOI: 10.1186/1471-2199-2-2 |
0.752 |
|
| 2001 |
Li Y, Podsypanina K, Liu X, Crane A, Tan LK, Parsons R, Varmus HE. Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice Bmc Molecular Biology. 2. DOI: 10.1186/1471-2199-2-2 |
0.663 |
|
| 2000 |
Schlosshauer PW, Brown SA, Eisinger K, Yan Q, Guglielminetti ER, Parsons R, Ellenson LH, Kitajewski J. APC truncation and increased β-catenin levels in a human breast cancer cell line Carcinogenesis. 21: 1453-1456. PMID 10874025 DOI: 10.1093/Carcin/21.7.1453 |
0.425 |
|
| 2000 |
Rubin MA, Gerstein A, Reid K, Bostwick DG, Cheng L, Parsons R, Papadopoulos N. 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer. Human Pathology. 31: 504-508. PMID 10821499 DOI: 10.1053/Hp.2000.6713 |
0.353 |
|
| 2000 |
De Vivo I, Gertig DM, Nagase S, Hankinson SE, O'Brien R, Speizer FE, Parsons R, Hunter DJ. Novel germline mutations in the PTEN tumour suppressor gene found in women with multiple cancers. Journal of Medical Genetics. 37: 336-41. PMID 10807691 DOI: 10.1136/Jmg.37.5.336 |
0.394 |
|
| 1999 |
Butler MP, Wang SI, Chaganti RS, Parsons R, Dalla-Favera R. Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas. Genes, Chromosomes & Cancer. 24: 322-7. PMID 10092130 DOI: 10.1002/(Sici)1098-2264(199904)24:4<322::Aid-Gcc5>3.0.Co;2-9 |
0.424 |
|
| 1999 |
Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems Proceedings of the National Academy of Sciences of the United States of America. 96: 1563-1568. PMID 9990064 DOI: 10.1073/Pnas.96.4.1563 |
0.725 |
|
| 1999 |
Shao X, Tandon R, Samara G, Kanki H, Yano H, Close LG, Parsons R, Sato T. Mutational analysis of thePTEN gene in head and neck squamous cell carcinoma.Int. J. Cancer,77, 684-688 (1998)Authors' erratum International Journal of Cancer. 80: 636-636. DOI: 10.1002/(Sici)1097-0215(19990209)80:4<636::Aid-Ijc27>3.0.Co;2-T |
0.348 |
|
| 1998 |
Shao X, Tandon R, Samara G, Kanki H, Yano H, Close LG, Parsons R, Sato T. Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma International Journal of Cancer. 77: 684-688. PMID 9688299 DOI: 10.1002/(Sici)1097-0215(19980831)77:5<684::Aid-Ijc4>3.0.Co;2-R |
0.431 |
|
| 1998 |
Cairns P, Evron E, Okami K, Halachmi N, Esteller M, Herman JG, Bose S, Wang SI, Parsons R, Sidransky D. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene. 16: 3215-8. PMID 9671402 DOI: 10.1038/Sj.Onc.1201855 |
0.443 |
|
| 1998 |
Bose S, Wang SI, Terry MB, Hibshoosh H, Parsons R. Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas Oncogene. 17: 123-127. PMID 9671321 DOI: 10.1038/Sj.Onc.1201940 |
0.355 |
|
| 1998 |
Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, Schramm J, Wiestler OD, Parsons R, Eng C, von Deimling A. PTEN mutations in gliomas and glioneuronal tumors. Oncogene. 16: 2259-64. PMID 9619835 DOI: 10.1038/Sj.Onc.1201756 |
0.436 |
|
| 1998 |
Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science (New York, N.Y.). 280: 1614-7. PMID 9616126 DOI: 10.1126/Science.280.5369.1614 |
0.465 |
|
| 1998 |
Peters N, Wellenreuther R, Rollbrocker B, Hayashi Y, Meyer-Puttlitz B, Duerr EM, Lenartz D, Marsh DJ, Schramm J, Wiestler OD, Parsons R, Eng C, Deimling AV. Analysis of the PTEN gene in human meningiomas Neuropathology and Applied Neurobiology. 24: 3-8. PMID 9549723 DOI: 10.1046/J.1365-2990.1998.00093.X |
0.413 |
|
| 1998 |
Parsons R. Molecular genetics of cancer: Second joint conference of the American association of cancer research and the European association for cancer research, September 9-13, 1997 Biochimica Et Biophysica Acta - Reviews On Cancer. 1377. PMID 9540813 DOI: 10.1016/S0304-419X(97)00034-6 |
0.324 |
|
| 1998 |
Parsons R. Phosphatases and tumorigenesis Current Opinion in Oncology. 10: 88-91. PMID 9466490 DOI: 10.1097/00001622-199801000-00014 |
0.433 |
|
| 1997 |
Arch EM, Goodman BK, Van Wesep RA, Liaw D, Clarke K, Parsons R, McKusick VA, Geraghty MT. Deletion of PTEN in a patient with Bannayan-Riley-Ruvalcaba syndrome suggests allelism with Cowden disease. American Journal of Medical Genetics. 71: 489-93. PMID 9286463 DOI: 10.1002/(Sici)1096-8628(19970905)71:4<489::Aid-Ajmg24>3.0.Co;2-B |
0.529 |
|
| 1997 |
Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, Parsons R, Tonks NK. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proceedings of the National Academy of Sciences of the United States of America. 94: 9052-7. PMID 9256433 DOI: 10.1073/Pnas.94.17.9052 |
0.465 |
|
| 1997 |
Marsh DJ, Dahia PL, Zheng Z, Liaw D, Parsons R, Gorlin RJ, Eng C. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nature Genetics. 16: 333-4. PMID 9241266 DOI: 10.1038/Ng0897-333 |
0.534 |
|
| 1997 |
Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genetics. 16: 64-7. PMID 9140396 DOI: 10.1038/Ng0597-64 |
0.618 |
|
| 1997 |
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, ... ... Parsons R, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (New York, N.Y.). 275: 1943-7. PMID 9072974 DOI: 10.1126/Science.275.5308.1943 |
0.813 |
|
| 1997 |
Mulcahy GM, Goggins M, Willis D, Decker RA, Luce MC, Parsons R, Markowitz SD, Narod SA, Holt JT, Page DL, Mauer AM, Thor A. Pathology and genetic testing : Workshop No. 6 Cancer. 80: 636-648. DOI: 10.1002/(Sici)1097-0142(19970801)80:3+<636::Aid-Cncr18>3.0.Co;2-F |
0.351 |
|
| 1997 |
Parsons R. Molecular genetics and hereditary cancer: Hereditary nonpolyposis colorectal carcinoma as a model Cancer. 80: 533-536. DOI: 10.1002/(Sici)1097-0142(19970801)80:3+<533::Aid-Cncr2>3.0.Co;2-A |
0.412 |
|
| 1996 |
Liu B, Parsons R, Papadopoulos N, Nicolaides NC, Lynch HT, Watson P, Jass JR, Dunlop M, Wyllie A, Peltomäki P, de la Chapelle A, Hamilton SR, Vogelstein B, Kinzler KW. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nature Medicine. 2: 169-74. PMID 8574961 DOI: 10.1038/Nm0296-169 |
0.391 |
|
| 1995 |
Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (New York, N.Y.). 268: 1336-8. PMID 7761852 DOI: 10.1126/Science.7761852 |
0.357 |
|
| 1995 |
Liu B, Nicolaides NC, Markowitz S, Willson JKV, Parsons RE, Jen J, Papadopolous N, Peltomäki P, de la Chapelle A, Hamilton SR, Kinzler KW, Vogelstein B. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability Nature Genetics. 9: 48-55. PMID 7704024 DOI: 10.1038/Ng0195-48 |
0.364 |
|
| 1995 |
Hamilton SR, Parsons RE, Papadopoulos N, Jen J, Powell SM, Krush AJ, Berk T, Cohen Z, Tetu B, Burger PC, Wood PA, Taqi F, Booker SV, Petersen GM, Offerhaus GJA, et al. The molecular basis of Turcot's syndrome New England Journal of Medicine. 332: 839-847. PMID 7661930 DOI: 10.1056/Nejm199503303321302 |
0.359 |
|
| 1995 |
Parsons R, Li GM, Longley M, Modrich P, Liu B, Berk T, Hamilton SR, Kinzler KW, Vogelstein B. Mismatch repair deficiency in phenotypically normal human cells Science. 268: 738-740. PMID 7632227 DOI: 10.1126/Science.7632227 |
0.406 |
|
| 1995 |
Papadopoulos N, Nicolaides NC, Liu B, Parsons R, Lengauer C, Palombo F, D'Arrigo A, Markowitz S, Willson JK, Kinzler KW. Mutations of GTBP in genetically unstable cells. Science (New York, N.Y.). 268: 1915-7. PMID 7604266 DOI: 10.1126/Science.7604266 |
0.39 |
|
| 1995 |
Liu B, Farrington SM, Petersen GM, Hamilton SR, Parsons R, Papadopoulos N, Fujiwara T, Jen J, Kinzler KW, Wyllie AH, Vogelstein B, Dunlop MG. Genetic instability occurs in the majority of young patients with colorectal cancer. Nature Medicine. 1: 348-52. PMID 7585065 DOI: 10.1038/Nm0495-348 |
0.307 |
|
| 1994 |
Parsons R, Li GM, Longley MJ, Fang WH, Papadopoulos N, Jen J, de la Chapelle A, Kinzler KW, Vogelstein B, Modrich P. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell. 75: 1227-36. PMID 8261516 DOI: 10.1016/0092-8674(93)90331-J |
0.433 |
|
| 1994 |
Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, Peltomäki P, Sistonen P, Aaltonen LA, Nyström-Lahti M. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell. 75: 1215-25. PMID 8261515 DOI: 10.1016/0092-8674(93)90330-S |
0.423 |
|
| 1993 |
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75: 817-25. PMID 8242752 DOI: 10.1016/0092-8674(93)90500-P |
0.434 |
|
| Show low-probability matches. |